logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Jin-Yuan Shih

National Taiwan University Hospital
H指数:63
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study

EGFR突变状态、治疗模式及辅助EGFR-TKI批准前的可切除早期非小细胞肺癌的结局：一项国际真实世界研究

Lung Cancer
IF4.4
2026-02-280
PRE
Steven H. Lin; Doreen A Kahangire; Saurabh P Nagar; Myung-Ju Ahn; Raafet Affi; Jason Agulnik; Jin–Yuan Shih; Maximilian J Hochmair; Amanda Tufman; Didier Debieuvre; Jason Chow; Maria Jimenez; Keith L. Davis; Martin Sandelin; Rajwanth R. Veluswamy
Clinical utility of pleural effusion supernatant cell-free DNA genotyping in previously treated patients with advanced non-small-cell lung cancer and disease progression: a multicenter retrospective study

胸水上清液游离DNA基因分型在既往接受治疗且疾病进展的晚期非小细胞肺癌患者中的临床应用价值：一项多中心回顾性研究

ESMO Open
IF8.3
2025-12-290
OAAI
S.-C. Chang; C.-Y. Huang; Y.-C. Lai; M.-S. Hsieh; C.-C. Ho; C.-Y. Yang; J.-Y. Shih; S.-G. Wu; P.-W. Hu; C.-L. Hsu; C.-Y. Chen; W.-Y. Liao
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study

BOS172738，一种选择性RET抑制剂，用于治疗RET基因变异的肿瘤患者，包括RET融合阳性的非小细胞肺癌和RET突变型甲状腺髓样癌：一项多中心I期剂量递增/扩展研究

ESMO Open
IF8.3
2025-09-240
PREAI
P. Schöffski; A. Gazzah; J. Trigo; A. Italiano; P. Gougis; V. Subbiah; J.-Y. Shih; H.H. Loong; B. Doger; M. Keegan; B. Jeglinski; K. Andreas; B.C. Cho
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

增强型与标准皮肤管理联合阿曼曲妥珠单抗-拉泽替尼在EGFR突变型晚期NSCLC中的应用比较：COCOON全球随机对照试验

Journal of Thoracic Oncology
IF20.8
2025-09-090
OAAI
Byoung Chul Cho; Weimin Li; Alexander I. Spira; Maxwell Sauder; Jill Feldman; Farastuk Bozorgmehr; Milena Mak; Janellen Smith; Pei Jye Voon; Baogang Liu; Panwen Tian; Jiunn-Liang Tan; Cheng-Ta Yang; Jin-Yuan Shih; Nuri Karadurmus; Juan Esteban Cundom; Glaucio Bertollo; Irfan Cicin; Jorge Nieva; Ana Laura Ortega-Granados; Pascale Tomasini; Danny Nguyen; Enriqueta Felip; Julia Schuchard; Sean P. Murphy; Bailey G. Anderson; Tonatiuh Romero; Yichuan Xia; Shubin Sheng; Joshua M. Bauml; Parthiv J. Mahadevia; Julian Kam; Mehregan Nematian-Samani; Jairo Simoes; Mark Wildgust; Nicolas Girard
Preventing Infusion-Related Reactions With Intravenous Amivantamab—Results From SKIPPirr, a Phase 2 Study: A Brief Report

预防静脉注射Amivantamab相关反应：SKIPPirr一项2期研究的成果——简报

Journal of Thoracic Oncology
IF20.8
2025-01-240
OAAI
Alexander I. Spira; Luis Paz-Ares; Ji-Youn Han; Jin-Yuan Shih; Céline Mascaux; Upal Basu Roy; Jon Zugazagoitia; Yu Jung Kim; Chao-Hua Chiu; Sang-We Kim; Ernest Nadal; Ignacio Gil-Bazo; Sean P. Murphy; Bailey G. Anderson; Yichuan Xia; George Wang; Joshua M. Bauml; Marc Chioda; Jairo Simoes; Parthiv J. Mahadevia; Gilberto Lopes
Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis

Atezolizumab，bevacizumab，培美曲塞和铂类用于EGFR TKI失败后的EGFR突变NSCLC患者: 免疫细胞谱分析的II期研究

CLINICAL AND TRANSLATIONAL MEDICINE
IF6.8
2024-12-230
OA
Wu, Shang-Gin; Ho, Chao-Chi; Yang, James Chih-Hsin; Yu, Shu-Han; Lin, Yen-Feng; Lin, Shu-Chin; Liao, Bin-Chi; Yang, Ching-Yao; Lin, Yen-Ting; Yu, Chong-Jen; Chuang, Ya-Ting; Liao, Wei-Yu; Yap, Kah Yi; Kou, Weng Si; Shih, Jin-Yuan
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study

PD-L1表达和免疫谱分析无法预测携带EGFR T790 M突变的肺癌中osimertinib的疗效：一项转化研究

Journal of the Formosan Medical Association
IF2.5
2024-12-170
OAAI
Ching-Yao Yang; Wei-Yu Liao; Chao-Chi Ho; Kuan-Yu Chen; Tzu-Hsiu Tsai; Chia-Lin Hsu; Kang-Yi Su; Yih-Leong Chang; Chen-Tu Wu; Chia-Chi Hsu; Yi-Nan Liu; Guan-Ru Peng; Almanzo Aeterna Kangartaputra; Shu-Han Yu; Bin-Chi Liao; Wei-Hsun Hsu; Jih-Hsiang Lee; Chia-Chi Lin; Jin-Yuan Shih; James Chih-Hsin Yang
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC

RELAY研究：厄洛替尼联合ramucirumab或安慰剂在未治疗、EGFR突变型转移性NSCLC中的最终总生存期

JOURNAL OF THORACIC ONCOLOGY
IF20.8
2024-11-015
PRE
Nakagawa, Kazuhiko; Garon, Edward B.; Seto, Takashi; Nishio, Makoto; Aix, Santiago Ponce; Paz-Ares, Luis; Chiu, Chao-Hua; Park, Keunchil; Novello, Silvia; Nadal, Ernest; Nishino, Kazumi; Yoh, Kiyotaka; Shih, Jin-Yuan; Chik, Jeannie Y. K.; Moro-Sibilot, Denis; Puri, Tarun; Varughese, Sunoj Chacko; Frimodt-Moller, Bente; Visseren-Grul, Carla; Reck, Martin

研究方向

暂未获取到该数据
C
Chong‐Jen Yu
H 指数:89论文数:966被引数:3.7万
J
James Chih‐Hsin Yang
H 指数:141论文数:1,223被引数:10.9万
P
Pan‐Chyr Yang
H 指数:121论文数:1,368被引数:6.3万
C
Chao‐Chi Ho
H 指数:37论文数:276被引数:5,702
S
Shang‐Gin Wu
H 指数:31论文数:120被引数:3,469
W
Wei‐Yu Liao
H 指数:35论文数:134被引数:3,428
Y
Yih‐Leong Chang
H 指数:62论文数:494被引数:1.3万
C
Ching‐Yao Yang
H 指数:18论文数:85被引数:1,714
C
Chia‐Lin Hsu
H 指数:25论文数:94被引数:2,192
M
Meng‐Feng Tsai
H 指数:23论文数:136被引数:2,405